By Fineline Cube 
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered Cipla Limited (BOM: 500087, NSE: CIPLA). Under the deal, CSPC Pharma grants Cipla’s US unit commercialization rights to its irinotecan liposome injection in the United States.
Financial Terms of the Agreement
As part of the agreement, CSPC Pharma will receive an upfront payment of USD 15 million. The company is also eligible to receive up to USD 25 million in initial commercial and regulatory payments, as well as up to USD 1.025 billion in additional commercial milestone payments. Additionally, CSPC Pharma will earn double-digit tiered net sales-based royalties.
About Irinotecan Liposome Injection
Irinotecan liposome injection is a sterile, white-to-pale-yellow opaque isotonic liposome dispersion containing 43 mg/10 mL irinotecan. The drug is indicated for the treatment of metastatic pancreatic cancer, colorectal cancer, lung cancer, and cervical cancer. It is also a component of combination therapies such as FOLFIRI and FOLFIRINOX regimens.-Fineline Info & Tech